Skip to main content
TipRanks
Go Ultimate75% OFF

Medexus Pharmaceuticals Inc (P731) Ratios

2 Followers

Medexus Pharmaceuticals Inc Ratios

DE:P731's free cash flow for Q2 2027 was C$5.09M. For the 2027 fiscal year, DE:P731's free cash flow was decreased by C$-30.22K and operating cash flow was C$5.12M. See a summary of the company’s cash flow.

Financial ratios
RatiosMar 26Mar 24Mar 23Mar 22Mar 21
Liquidity Ratios
Current Ratio1.191.090.650.821.47
Quick Ratio0.570.630.440.461.10
Cash Ratio0.120.080.160.210.59
Solvency Ratio0.070.040.050.03-0.16
Operating Cash Flow Ratio0.350.28-0.01-0.020.13
Short-Term Operating Cash Flow Coverage8.531.19-0.03-0.060.38
Net Current Asset ValueC$ -34.51MC$ -52.91MC$ -114.73MC$ -102.71MC$ -71.92M
Leverage Ratios
Debt-to-Assets Ratio0.150.320.590.390.38
Debt-to-Equity Ratio0.451.654.223.083.13
Debt-to-Capital Ratio0.310.620.810.760.76
Long-Term Debt-to-Capital Ratio0.290.530.540.690.65
Financial Leverage Ratio3.015.147.197.838.24
Debt Service Coverage Ratio1.690.650.310.52-0.87
Interest Coverage Ratio1.120.810.56-1.23-0.14
Debt to Market Cap0.221.382.640.950.39
Interest Debt Per Share0.852.835.423.454.38
Net Debt to EBITDA1.242.324.772.79-1.39
Profitability Margins
Gross Profit Margin54.78%52.64%55.54%49.45%52.73%
EBIT Margin2.95%11.91%7.92%10.96%-39.56%
EBITDA Margin12.75%17.05%14.93%19.77%-29.63%
Operating Profit Margin5.87%9.55%7.04%-19.55%-1.73%
Pretax Profit Margin-2.29%0.09%-4.66%-4.98%-39.54%
Net Profit Margin-2.41%-0.19%1.13%-3.75%-35.48%
Continuous Operations Profit Margin-2.41%-0.19%1.13%-3.75%-35.48%
Net Income Per EBT105.28%-201.89%-24.22%75.37%89.72%
EBT Per EBIT-38.97%0.98%-66.21%25.47%2289.32%
Return on Assets (ROA)-1.63%-0.14%0.76%-2.07%-19.03%
Return on Equity (ROE)-4.89%-0.71%5.44%-16.18%-156.87%
Return on Capital Employed (ROCE)6.23%12.06%15.70%-18.96%-1.27%
Return on Invested Capital (ROIC)6.08%-20.71%-1.74%-11.55%-1.01%
Return on Tangible Assets-3.20%-0.26%1.51%-5.54%-45.96%
Earnings Yield-2.37%-0.60%3.82%-4.71%-23.54%
Efficiency Ratios
Receivables Turnover6.694.703.645.323.37
Payables Turnover5.466.914.732.572.53
Inventory Turnover1.351.742.101.822.57
Fixed Asset Turnover235.38145.31120.2462.82100.20
Asset Turnover0.670.730.670.550.54
Working Capital Turnover Ratio-30.40-6.73-4.2520.186.50
Cash Conversion Cycle258.36234.53196.65127.78106.61
Days of Sales Outstanding54.5977.58100.2768.56108.43
Days of Inventory Outstanding270.57209.78173.53200.99142.17
Days of Payables Outstanding66.8152.8377.15141.77143.99
Operating Cycle325.16287.36273.80269.55250.60
Cash Flow Ratios
Operating Cash Flow Per Share0.580.84-0.07-0.060.33
Free Cash Flow Per Share0.120.83-0.09-0.46-0.38
Dividend Paid and CapEx Coverage Ratio1.2570.35-3.99-0.150.47
Capital Expenditure Coverage Ratio1.2570.35-3.99-0.150.47
Operating Cash Flow Coverage Ratio0.850.38-0.02-0.020.09
Operating Cash Flow to Sales Ratio0.190.17-0.01-0.020.06
Free Cash Flow Yield3.69%51.33%-5.65%-14.56%-4.76%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-44.57-167.9326.18-21.22-4.25
Price-to-Sales (P/S) Ratio1.020.320.300.801.51
Price-to-Book (P/B) Ratio2.061.191.423.436.66
Price-to-Free Cash Flow (P/FCF) Ratio27.101.95-17.70-6.87-21.00
Price-to-Operating Cash Flow Ratio5.341.92-22.13-51.7723.83
Price-to-Earnings Growth (PEG) Ratio0.251.50-0.180.23-0.01
Enterprise Value Multiple9.214.186.766.82-6.48
Enterprise Value116.57M80.58M109.02M103.42M152.95M
EV to EBITDA9.214.186.766.82-6.48
EV to Sales1.170.711.011.351.92
EV to Free Cash Flow31.344.37-60.36-11.63-26.75
EV to Operating Cash Flow6.184.31-75.50-87.6530.36
Tangible Book Value Per Share-0.73-1.98-5.36-5.13-4.54
Shareholders’ Equity Per Share1.521.361.120.911.19
Tax and Other Ratios
Effective Tax Rate-0.053.021.240.250.10
Revenue Per Share3.075.065.413.945.24
Net Income Per Share-0.07-0.010.06-0.15-1.86
Tax Burden1.05-2.02-0.240.750.90
Interest Burden-0.780.01-0.59-0.451.00
Research & Development to Revenue0.090.070.030.100.06
SG&A to Revenue0.400.250.340.380.24
Stock-Based Compensation to Revenue0.000.000.010.020.02
Income Quality-7.88-87.45-1.180.41-0.18

Currency in CAD